The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | GLOW trial updates: predicting outcomes using genomic aberrations and MRD status
In this video, Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, provides an update of the Phase III GLOW trial (NCT03462719), which evaluated efficacy and safety of fixed-duration ibrutinib-venetoclax in elderly patients with previously untreated chronic lymphocytic leukemia (CLL). Dr Kater and his team are utilizing the trial data to investigate whether genomic aberrations and measurable residual disease (MRD) status of patients allow for prediction of future clinical outcomes. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
